Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-043-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Well documented and reported study fully adequate for assessment. The study was conducted according to internationally accepted technical guidelines and in compliance with GLP in a recognized contract research organization.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- (17th Dec. 2001)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Version / remarks:
- (30th May 2008)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS: CRL:(WI) rats
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at study initiation: adult rats, 8 weeks old
- Weight at study initiation: 192 – 207 g
- Fasting period before study: the night before treatment (water ad libitum)
- Housing: 3 animals / cage (Type II polypropylene/polycarbonate)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 (+/- 3)
- Humidity (%): 30-70
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: 200 mg/ml
- Amount of vehicle (if gavage): 10 ml/kg b.w.
MAXIMUM DOSE VOLUME APPLIED: ca. 2 ml
DOSAGE PREPARATION: The test material mixed with the vehicle was warmed up on a water bath to 50 ºC for approximately 10 minutes thus facilitating preparation of a suitable dose formulation. Pending administration to the animals, the dose formulation was stirred on a magnetic stirrer at room temperature and was protected from light. - Doses:
- 2000 mg/kg b.w.
- No. of animals per sex per dose:
- 2 x 3 female rats /2000 mg/kg b.w. (incl. the confirmatory group)
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of clinical observations: 30 min., 1, 2, 3, 4, 6 h after administration, daily for 14 days
weighing: day before treatment (day -1), day of treatment prior to dosing (day 0) and than weekly
- Necropsy of all animals performed: yes - Key result
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: no deaths
- Mortality:
- no mortality
- Clinical signs:
- other: Treatment with WS400104 at the dose of 2000 mg/kg bw caused transient decreased activity, hunched back and incoordination in all of six animals on the day of treatment. All animals recovered on Day 1.
- Gross pathology:
- No macroscopic observed effects
- Interpretation of results:
- other: not acutely toxic
- Conclusions:
- Under the conditions of this study, the acute oral LD50 value of the test item WS400104 was found to be above 2000 mg/kg bw in female CRL:(WI) rats.
According to the Globally Harmonised System (GHS) (UNITED NATIONS 2005 and more recent revisions) and according to Regulation (EC) No 1272/2008 WS400104 should be ranked as "Unclassified" for acute oral exposure.
Reference
Table 1: CLINICAL OBSERVATIONS:DOSE: 2000mg/kg b.w., Treatment on Day 0
CageNo. |
Animal Number |
Observations |
Observationdays |
|
|||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6-14 |
|||||||||
30' |
1h |
2h |
3h |
4h |
6h |
||||||||||
1 |
1176 |
SymptomFree |
- |
- |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
|
Activitydecreased |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
1177 |
SymptomFree |
- |
- |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
Activitydecreased |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
1178 |
SymptomFree |
- |
- |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
Activitydecreased |
1 |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
+ |
+ |
+ |
+ |
+ |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
1 |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
2 |
1179 |
SymptomFree |
+ |
- |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
|
Activitydecreased |
- |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
- |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
1180 |
SymptomFree |
+ |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
Activitydecreased |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
- |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
1181 |
SymptomFree |
+ |
- |
- |
- |
- |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
|
|
Activitydecreased |
- |
- |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
||
Hunchedback |
- |
- |
+ |
+ |
- |
- |
- |
- |
- |
- |
- |
- |
|
||
Incoordination |
- |
1 |
1 |
1 |
1 |
- |
- |
- |
- |
- |
- |
- |
|
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In the acute oral toxicity study no death occured at the highest recommended dose of 2000 mg/kg.
Justification for classification or non-classification
In the acute oral toxicity study, all animals survived the dose of 2000 mg/kg. Therefore, classification of WS400104 for acute oral toxicity is not required [REGULATION (EC) 1272/2008].
Non-classification of WS400104 by the dermal route was reasonable, because of the absence of effects indicative of relevant systemic toxicity (apart from the sensitization response) and local irritation in all available in vivo toxicity studies with WS400104 and the systemic exposure probably being higher by the oral than by the dermal administration route.
Non-classification of WS400104 by the inhalation route was justified, because WS400104 has a very low vapour pressure and is a highly viscous liquid, making the inhalation exposure of humans to vapour or a droplet aerosol unlikely
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.